Because orforglipron is a small-molecule compound rather than a peptide, the body can absorb it rapidly and reliably without requiring any special timing around food or water intake
No, patients should not discontinue or replace DMARD therapy with GLP-1 medications
Arterioscler Thromb Vasc Biol (2012) 32:15139
IVIM results of 26.54% slightly exceed this, though direct comparisons between clinical trials and real-world observational studies require caution due to differences in patient selection, adherence monitoring, and measurement methods
However, despite significant weight loss, liraglutide-treated animals displayed increased bone mass, trabecular number, and cortical thickness in the appendicular and axial skeletons, with marked improvement in bone formation parameters [55,56,57]